



Mithra announces new agreement with GSP for development of an additional injectable

- **Agreement with Generic Specialty Pharma (GSP), a leading generics player, for development and supply of a fifth hormonal injectable**
- **Expansion of Mithra CDMO's portfolio of activities, confirming its profile as a unique industrial partner in the development and production of a complete range of specialized medical products and devices.**

Liege, Belgium, 18 April 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces that it has entered into a new agreement with Generic Speciality Pharma (GSP) for the development and supply of a sterile hormonal injectable product at Mithra CDMO¹. Headquartered in Dublin, GSP is part of the Alter Pharma group, a Belgian pharmaceutical conglomerate focused on the development and manufacturing of niche generics, complex generics and high added value products.

This contract follows the first collaboration agreement concluded with GSP in 2017 for the development of four injectable products and confirms GSP's confidence in the technological know-how of Mithra CDMO in this complex field of activity. In addition to this major partnership, Mithra has been working on the development of a sterile injectable for the German group Midas Pharma since 2018. Thanks to its tripled production capacity and the acquisition of new equipment, Mithra CDMO is continuing to deploy its range of services, both in the Injectables division and for other complex therapeutic solutions.

François Fornieri, CEO Mithra Women's Health, comments: *"This new contract for our Injectables division confirms the excellent relationship established with GSP from the start of the development of their first four injectables at Mithra CDMO and demonstrates their confidence in our expertise and know-how. To meet the growing demand of our various partners, we have increased our production capacities and are constantly strengthening our R&D and production teams to offer a quality service throughout the development process."*

¹ Contract Development & Manufacturing Organization

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra's unique native estrogen platform, E4 (Esetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To receive our press releases by email, please subscribe to our mailing list on investors.mithra.com